Gut Hormones in Health and Obesity: the Upcoming Role of Short Chain Fatty Acids
Total Page：16
File Type：pdf, Size：1020Kb
nutrients Review Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids Habeeb Alhabeeb 1,* , Ali AlFaiz 1, Emad Kutbi 1, Dayel AlShahrani 1, Abdullah Alsuhail 1, Saleh AlRajhi 2, Nemer Alotaibi 3, Khalid Alotaibi 3, Saad AlAmri 1, Saleh Alghamdi 1 and Naji AlJohani 4 1 Research Center, King Fahad Medical City—KFMC, Riyadh 11525, Saudi Arabia; [email protected] (A.A.); [email protected] (E.K.); [email protected] (D.A.); [email protected] (A.A.); [email protected] (S.A.); [email protected] (S.A.) 2 Family Medicine, King Fahad Medical City—KFMC, Riyadh 11525, Saudi Arabia; [email protected] 3 College of Medicine, Shaqra University, Shaqra 11961, Saudi Arabia; [email protected] (N.A.); [email protected] (K.A.) 4 Obesity, Endocrine, and Metabolism Center, King Fahad Medical City—KFMC, Riyadh 11525, Saudi Arabia; [email protected] * Correspondence: [email protected] Abstract: We are currently facing an obesity pandemic, with worldwide obesity rates having tripled since 1975. Obesity is one of the main risk factors for the development of non-communicable diseases, which are now the leading cause of death worldwide. This calls for urgent action towards understanding the underlying mechanisms behind the development of obesity as well as developing more effective treatments and interventions. Appetite is carefully regulated in humans via the interaction between the central nervous system and peripheral hormones. This involves a delicate balance in external stimuli, circulating satiating and appetite stimulating hormones, and correct functioning of neuronal signals. Any changes in this equilibrium can lead to an imbalance in energy intake versus expenditure, which often leads to overeating, and potentially weight gain resulting in Citation: Alhabeeb, H.; AlFaiz, A.; overweight or obesity. Several lines of research have shown imbalances in gut hormones are found Kutbi, E.; AlShahrani, D.; Alsuhail, A.; in those who are overweight or obese, which may be contributing to their condition. Therefore, this AlRajhi, S.; Alotaibi, N.; Alotaibi, K.; review examines the evidence for targeting gut hormones in the treatment of obesity by discussing AlAmri, S.; Alghamdi, S.; et al. Gut how their dysregulation influences food intake, the potential possibility of altering the circulating Hormones in Health and Obesity: The Upcoming Role of Short Chain levels of these hormones for treating obesity, as well as the role of short chain fatty acids and protein Fatty Acids. Nutrients 2021, 13, 481. as novel treatments. https://doi.org/10.3390/nu13020481 Keywords: obesity; gut hormones; short chain fatty acids; diabetes; overweight; food intake; appetite; Received: 12 December 2020 glucagon-like peptide-1; peptide tyrosine tyrosine; neuropeptide Y Accepted: 30 December 2020 Published: 31 January 2021 Publisher’s Note: MDPI stays neutral 1. Introduction with regard to jurisdictional claims in Historically, humanity has dealt with countless famines, where the scarcity of food published maps and institutional affil- resulted in starvation and significant loss of life. However, today we are facing a different iations. weight associated epidemic, obesity [1]. Obesity is a complex condition that, in simple terms, is caused by a chronic imbalance between energy intake and energy expenditure, and is defined as a body mass index greater than 30 kg/m2. Since 1975, the level of obesity worldwide has almost tripled [2]. According to World Health Organization data, Copyright: © 2021 by the authors. 1.9 billion people worldwide are overweight, with 650 million of those considered obese [2]. Licensee MDPI, Basel, Switzerland. Data from the Health Survey for England carried out in 2017 revealed that in the United This article is an open access article Kingdom, 28.1% of adults are obese, and predict that this number would rise to 48% of the distributed under the terms and population by 2030 [3]. Furthermore, in the United States of America, 42.4% of adults were conditions of the Creative Commons considered obese in 2017–2018 [4]. Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Nutrients 2021, 13, 481. https://doi.org/10.3390/nu13020481 https://www.mdpi.com/journal/nutrients Nutrients 2021, 13, 481 2 of 20 2. Obesity Related Diseases Non-communicable diseases, which are associated with obesity, are the leading cause of death worldwide [5]. Obesity is linked to an increased risk of developing a variety of these diseases such as type 2 diabetes mellitus (T2DM), coronary heart disease, stroke and certain types of cancer [6–9]. The predicted increase in prevalence of obesity by 65 million people in the USA and 11 million in the UK is expected to lead to an additional 8·5 million cases of diabetes, 5.7–7.3 million cases of heart disease and stroke and 492,000– 669,000 additional cases of cancer in both countries by 2030 [10]. Furthermore, conservative estimates of the burden of disease indicators in children predict that 20,000 obese children in Europe have T2DM, a further 400,000 have impaired glucose tolerance, and over 1 million are likely to show a range of indicators for cardiovascular disease, including hypertension and raised cholesterol levels and have three or more indicators of metabolic syndrome. Finally, over 1.4 million children may have early stages of liver disorder linked with non- alcoholic fatty liver disease [11]. While these conditions have typically been characteristic to Western countries, their prevalence is now rising in developing countries, leading to a double burden of non-communicable diseases and undernutrition. Rapid action is required to stop this global rise in obesity [1]. In addition to significantly impacting patients’ quality of life, the obesity epidemic places a huge burden on health services [10]. A systematic review on the economic burden of obesity worldwide by Withrow and Alter (2011) found that medical expenses for obese individuals can be 6%–45% higher than for their normal weight counterparts. Globally, between 0.7% and 2.8% of a country’s total health expenditure is associated with obesity related costs. Estimates suggest that in the UK, the National Health Service spent £6.1 billion on overweight and obesity related ill-health in 2014–2015, which is expected to rise to £9.7 billion by 2050 [12]. There was also a reported wider societal cost of £27 billion. Furthermore, in 2016 the US spent $480.7 billion on direct obesity-related healthcare costs, and there was an estimated indirect societal cost of $1.24 trillion [13]. The remarkable prevalence of obesity and its consequences on overall health have led to calls to identify the root causes of obesity and potential treatments. At a societal level, obesity can be considered as a product of the modern Western lifestyle, resulting from obesogenic environments with the wide availability of convenient high-reward and calorie- dense foods, excessive portions and lack of daily exercise [14]. Research has revealed that obesity can also have a small genetic component. This can take the form of a monogenic disorder in more extreme cases, such as possessing mutations in genes involved in the leptin/melanocortin axis [15], but is more often seen as a polygenic disorder affecting many different genes. In these cases, most of the genes involved are linked with appetite regulation [16]. This link between obesity and appetite regulation highlights the importance of the gut–brain axis in body weight homeostasis, through the lens of satiation [17]. In principle, food ingestion in humans results in gastric distension and secretion of hormones associated with satiety, leading to a short-term reduction in food intake [18–20]. In the first instance, treatment for obesity involves lifestyle interventions to change dietary and physical activity patterns to promote weight loss. However, these interventions are often unsuccessful [21–23]. The National Institute of Care and Excellence (NICE) states that if lifestyle changes are found to be ineffective, pharmacological treatments may be considered [24]. Despite the urgency for effective medical treatments for obesity, to date the options are limited. The sole drug treatment available in the UK, Orlistat, does not yield impressive results regarding long-term weight loss [25], and is associated with gastrointestinal side effects [26]. If these methods have failed, health care practitioners may then discuss weight loss surgery with patients. The only treatment that drastically improves patients’ weight management in a sustainable way is the Roux-en-Y gastric bypass (RYGB) surgery. However, this is a costly, invasive procedure with side effects, that may not always be effective for everyone, for example in elderly patients [27,28]. Furthermore, up to 20% of patients who undergo RYGB experience significant weight regain [29]. Intriguingly, weight loss post-surgery also coincides with an altered pattern of Nutrients 2021, 13, 481 3 of 20 secretion of gut hormones that control appetite [30–32]. Collectively, both genetic evidence and data from patients who have undergone bariatric surgery highlight the contribution of appetite control to obesity through the role of satiety-inducing gut hormones [15,27,32–34]. 3. Appetite Regulation Appetite in humans is carefully regulated by a complex system of neural signals, hormones and external stimuli, which manage the intake of food [33]. This regulation system can be broken down into central regulation involving the arcuate nucleus of the hypothalamus, and peripheral regulation via hormones which are released in the gut or elsewhere. This system requires a delicate balance of signals to function optimally, and its dysregulation can lead to imbalances in energy input compared to output, eventually leading to weight gain and obesity [35]. Appetite regulation can have both homeostatic and hedonic elements [35,36]. Homeostatic appetite control involves the regulation of energy intake needed for bodily functioning and to keep body weight static.